The first data suggesting that restoration of lost brain function may be possible was announced today in a new paper detailing a study that linked patient-reported outcomes and biological markers to Microtesla Magnetic Therapy (MMT). David Putrino, Ph.D., Nash Family Director of the Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai and lead investigator of the study, pictured at right, presented the data at the inaugural International Society of Long COVID & Post-Acute Infection Syndromes (ISLC-PAIS) conference in Amsterdam. Dr. Blake Gurfein, pictured at left, is co-founder and CEO of Fareon, a biophysics company pioneering MMT, the low-intensity, radiofrequency electromagnetic field that passes unimpeded through the skull and reaches deep brain structures.
The first data suggesting that restoration of lost brain function may be possible was announced today in a new paper detailing a study that linked patient-reported outcomes and biological markers to Microtesla Magnetic Therapy (MMT). David Putrino, Ph.D., Nash Family Director of the Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai and lead investigator of the study, pictured at right, presented the data at the inaugural International Society of Long COVID & Post-Acute Infection Syndromes (ISLC-PAIS) conference in Amsterdam. Dr. Blake Gurfein, pictured at left, is co-founder and CEO of Fareon, a biophysics company pioneering MMT, the low-intensity, radiofrequency electromagnetic field that passes unimpeded through the skull and reaches deep brain structures.